Infectious Disease · Pediatrics · 4 h ago
Piperacillin-tazobactam modeling favors continuous infusion in critically ill children
A population pharmacokinetic study of 31 critically ill children found that only 22.6% achieved combined piperacillin and tazobactam exposure targets at a piperacillin MIC of 16 mg/L. Simulations favored continuous infusion, particularly with preserved or augmented renal clearance, but did not establish clinical benefit.
- Thirty-one children contributed 102 plasma samples.
- Only 22.6% achieved combined targets at a piperacillin MIC of 16 mg/L.
- Continuous infusion achieved the highest simulated target exposures.
- Clinical outcome benefits were not established.
A population pharmacokinetic study in Antimicrobial Agents and Chemotherapy evaluated piperacillin-tazobactam exposure in critically ill children aged 1 month to 12 years. Researchers collected 102 plasma samples from 31 patients around a single dose and developed a simultaneous model for both drugs. Monte Carlo simulations compared short, extended, and continuous infusions across ages and renal function states.
Combined dosing adequacy required free piperacillin concentrations above the minimum inhibitory concentration (MIC) throughout the dosing interval and free tazobactam concentrations above 2 mg/L for 85% of the interval. At a piperacillin MIC of 16 mg/L, only 22.6% of patients achieved both targets. Renal function and infusion duration were the main determinants of target attainment. Short infusions frequently failed, especially with preserved renal function or augmented renal clearance. Extended infusions improved attainment but remained suboptimal at higher MICs; continuous infusion produced the highest target exposures across simulated scenarios.
These findings support further evaluation of continuous infusion to optimize exposure in pediatric critical care. However, the study involved a small cohort, with sampling around only one dose, and comparisons between infusion strategies relied on simulations. Pharmacokinetic target attainment is not evidence of improved clinical outcomes. The supplied abstract does not provide detailed dosing schedules, safety results, or clinical efficacy outcomes.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Antimicrobial Agents and Chemotherapy: Population pharmacokinetics of piperacillin/tazobactam in critically ill pediatric patients ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.